Warner-lambert Company

Ann Holmes

Milton L Hoefle

Bruce D Roth

David Christopher Horwell

Bharat Kalidas Trivedi

Edward Roberts

Ila Sircar

William Howard Roark

Jurgen Kleinschroth

Reginald S Richardson

Janak Khimchand Padia

Paul Leroy Creger

Paul C Unangst

David Charles Rees

Martyn C Pritchard

Bradley Dean Tait

Michael D Mullican

Corinne E Augelli-Szafran

Julian Aranda

Uwe Trostmann

Hans-Jurgen Betche

Charlotte D Stratton

Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Cholecystokinin antagonists, their preparation and therapeutic use

Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, and opioids. The compounds are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.

Amino acid analogs as CCK antagonists

Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2- dimethylpentanamides which are useful in preventing the intestinal absorption of cholesterol and also increasing high-density lipoprotein (HDL) cholesterol, as well as novel pharmaceutical compositions and methods of use, as well as processes for their manufacture are herein described.

Novel

Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2-dimethylpen tan amides which are useful in preventing the intestinal absorption of cholesterol and also increasing high-density lipoprotein (HDL) cholesterol, as well as novel pharmaceutical compositions and methods of use, as well as processes for their manufacture are herein described.

Certain trisubstituted anilides of oleic, linoleic, and linolenic acid are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors

Certain substituted amides of saturated fatty acids are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol

Certain disubstituted pyrimidineamides of oleic and linoleic acids are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Pyrimidine amides of oleic or linoleic acid, composition containing them

Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol

Novel substituted benzimidazol-2-yl-phenoxyalkanoic acids, salts and esters thereof and 3H-imidazo[4,5-b]pyridin-2-yl phenoxy-alkanoic acid, salts, and esters which are useful as antiarteriosclerotic agents are disclosed. The compounds elevate the high density lipoprotein fraction of cholesterol and also lower the low density lipoprotein fraction of cholesterol. Methods for preparing and using the compounds are included.

Antiarteriosclerotic substituted benzimidazol-2-yl-and

New substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides which are useful as anti-arteriosclerotic agents are disclosed. These compounds elevate the high density lipoprotein fraction of cholesterol, and also lower the low density lipoprotein fraction of cholesterol.

Growing community of inventors

Dexter, MI, United States of America

Ann Holmes